Green Thumb Industries and Omeros Compared

Analysts see more upside potential in Omeros stock compared to Green Thumb Industries

Published on Feb. 23, 2026

Got story updates? Submit your updates here. ›

Green Thumb Industries (GTBIF) and Omeros (OMER) are both small-cap medical companies, but analysts believe Omeros has more favorable growth prospects. The article compares the two companies on factors like institutional ownership, valuation, profitability, and analyst ratings.

Why it matters

This comparison of two medical companies provides investors with insights to help them evaluate which stock may be the better investment opportunity based on factors like financial performance, growth potential, and analyst sentiment.

The details

The article notes that Omeros has stronger institutional ownership at 48.8% compared to just 0.1% for Green Thumb Industries. Omeros also has a lower price-to-earnings ratio, indicating it is currently more affordable. Analysts have a consensus target price of $40.33 for Omeros, implying 262% potential upside, compared to less bullish views on Green Thumb Industries. The article also looks at metrics like net margins, return on equity, and return on assets, finding Green Thumb Industries outperforms Omeros on most of these measures.

  • The article was published on February 23, 2026.

The players

Green Thumb Industries

A manufacturer, distributor, and retailer of cannabis products for medical and adult-use in the United States, operating through Retail and Consumer Packaged Goods segments.

Omeros Corporation

A clinical-stage biopharmaceutical company that discovers, develops, and commercializes small-molecule and protein therapeutics, targeting immunologic diseases, complement-mediated diseases, cancers, and addictive/compulsive disorders.

Got photos? Submit your photos here. ›

The takeaway

This comparison highlights how analysts see more growth potential in Omeros compared to Green Thumb Industries, despite Green Thumb's stronger financial performance on certain metrics. Investors will need to weigh the relative merits of each company's prospects when deciding which stock may be the better investment.